Borregaard (BRG) Pre-Close Call summary
Event summary combining transcript, slides, and related documents.
Pre-Close Call summary
12 Nov, 2025Executive summary
Sales volumes in BioSolutions are expected to reach 330,000 tons in 2025, with agriculture as the main growth driver and a positive product mix effect.
BioMaterials sales volume forecast for 2025 is 150,000 tons, at the low end of guidance due to tariff and trade war uncertainties, but with a higher share of specialized grades.
Fine Chemicals faces lower bioethanol prices due to increased supply, with volumes expected to rise compared to 2024.
Trading performance and revenue trends
Q2 BioSolutions sales volume is expected at 85,000 tons, seasonally higher but with a less favorable product mix.
Average price increase in BioSolutions was mainly due to product mix, not underlying price hikes.
BioMaterials average price in sales currency is expected to be 8%-10% higher in H1 2025 versus H1 2024.
Profitability and margins
Strong profit uplift in agriculture is driven by unique, green product properties and biocontrol focus.
Environmental investments, such as electrification, are reducing energy costs and CO2 emissions.
Higher spot energy prices are largely offset by reduced energy consumption from recent investments.
Latest events from Borregaard
- Record EBITDA, strong cash flow, higher dividend, and start-up impairments define the period.BRG
Q4 20254 Feb 2026 - BioSolutions strength offset weaker BioMaterials; outlook cautious amid rising costs.BRG
Q2 20243 Feb 2026 - Specialization, innovation, and sustainability drive robust growth and disciplined investment.BRG
CMD 202420 Jan 2026 - Q3 revenue and EBITDA rose on volume growth and expansion, but cost and market risks remain.BRG
Q3 202417 Jan 2026 - Strong growth, sustainability, and expansion drive value in advanced biorefinery markets.BRG
SEB Nordic Seminar presentation16 Jan 2026 - Record EBITDA and higher dividend driven by BioSolutions, with strong outlook for 2025.BRG
Q4 20249 Jan 2026 - 2025 outlook: stable volumes, higher biomaterials prices, lower bioethanol prices, and cost risks.BRG
Pre-Close Call26 Dec 2025 - Q4 guidance remains steady, with strong margins and lower costs offset by ongoing legal and market risks.BRG
Pre-Close Call18 Dec 2025 - Record BioSolutions results and improved margins drove EBITDA to NOK 511 million.BRG
Q1 202529 Nov 2025